PTC Therapeutics (PTCT) - Stock Price & Dividends

PTC Therapeutics Inc. (NASDAQ: PTCT) is a biopharmaceutical company that specializes in developing and delivering treatments for individuals with rare disorders. The company's robust portfolio pipeline consists of a range of commercial products and product candidates at different developmental stages, including clinical, pre-clinical, and research and discovery phases.

PTC Therapeutics focuses on developing therapies for a variety of therapeutic areas, particularly in the realm of rare diseases. The company offers Translarna and Emflaza for Duchenne muscular dystrophy treatment in specific regions, while also providing Tegsedi, Waylivra, and Evrysdi for rare disease treatment in various markets, including Latin America and Brazil.

Beyond its existing treatments, PTC Therapeutics is actively pursuing the development of cutting-edge therapies through its splicing, bio-e, metabolic, gene therapy, and oncology platforms. The company collaborates with industry leaders like F. Hoffman-La Roche Ltd, Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc. to drive drug discovery and research in regenerative medicine.

Founded in 1998 and headquartered in South Plainfield, New Jersey, PTC Therapeutics Inc.'s mission is to bring life-changing therapies to patients with unmet medical needs. To learn more about the company, visit their website at https://www.ptcbio.com.